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Abstract
Hepatitis C virus (HCV) infection is frequently associated with extrahepatic disorders, among which renal diseases are frequent. 
This article highlights the most frequent HCV-associated renal disorders, the impact of HCV infection on chronic renal disease 
and renal transplantation, and the role of current direct-acting antiviral therapies. HCV is associated with membranoproliferative 
glomerulonephritis, acceleration of end-stage renal diseases in patients with glomerulopathies, and a higher risk of death in patients 
affected by chronic kidney disease. Before the introduction of direct-acting antiviral drugs as treatment modality, renal transplan-
tation was a challenging clinical problem because the drugs available until 2011 obtained a poor sustained virologic response, had 
several side effects, and caused acute rejection when used after transplantation. The knowledge of the viral structure and its repli-
cation allowed the discovery of new classes of direct-acting antiviral drugs that revolutionized this scenario. These new drugs are 
comparatively more effective and safer. Accumulating evidence suggests that it is possible to cure HCV-related glomerulonephritis, 
and obtain a sustained virologic response in patients with renal failure, or on dialysis, before commencing transplantation. Finally, 
it became possible to transplant HCV-positive kidneys into HCV-positive or HCV-negative recipients.
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Introduction
Hepatitis C virus (HCV) infection is a relevant health 
issue  with 150–170 million people chronically infected 
 worldwide (1). These patients are at high risk of develop-
ing liver complications such as cirrhosis and liver cancer. 
A large proportion of patients with HCV infection are also 
affected by extrahepatic complications (2–5), as summarized 
in Table  1. Some of these clinical conditions are common, 
while  others are anecdotal or infrequently reported (2–5). 
This article provides an overview of renal disorders associated 
with HCV infection, their main characteristics, and therapy, 
with emphasis on direct-acting antiviral (DAA) therapies.
HCV epidemiology in patients affected 
by renal diseases
The prevalence of HCV infection in the general population 
is estimated to be approximately 3% (6). In dialysis patients, 
the prevalence is higher, and the Dialysis Outcomes and 
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Practice Patterns Study (DOPPS) reported prevalence rates 
ranging from 2.6% to 22.9% (7). Excluding dialysis patients, 
HCV prevalence is higher in patients with kidney diseases 
with respect to general population. HCV may cause chronic 
kidney disease (CKD) via specific forms of glomerulonephri-
tis (GN), primarily membranoproliferative GN (MPGN) 
which is associated with mixed cryoglobulinemia (MC). In 
such cases, MC represents HCV/anti-HCV immune complex 
in association with rheumatoid factor (RF) and comple-
ment (8). Epidemiological studies conducted in the United 
States (NHANES II) and Taiwan, where HCV infection is 
endemic, have documented the interaction and relationship 
between HCV infection and CKD (9, 10). The expression by 
renal parenchyma of CD81 and SRB1 receptor facilitates the 
binding of HCV to the renal cell surface and its endocytosis 
(11). Consequently, HCV-RNA and the related proteins have 
been found in the mesangial, tubular, epithelial, and endothe-
lial cells of the kidney (12, 13). HCV-associated renal injury 
may also be facilitated by the presence of toll-like receptors 
(TLRs) on renal cells. TLRs are able to recognize molecules 
associated with microbial pathogens and, once activated, 
may induce an immunological response (14). The increased 
expression of TLR3 on renal cells, observed in renal biopsy 
samples, may justify a link between TLR3 and HCV-related 
glomerular diseases.
HCV and CKD
HCV infection is frequently associated with CKD stages 4 
and 5. Blood transfusions and nosocomial transmission in 
dialysis patients are the causes of the higher prevalence of 
HCV infection in these patients when compared with the 
general population. In patients on dialysis, the nosocomial 
transmission also seems to occur independently of blood 
transfusions (15–17). In one study, of the 1423 hemodialysis 
patients who never received previous blood transfusions, 18% 
had hepatitis C antibodies (15). In addition to a higher fre-
quency, epidemiological studies have demonstrated that HCV 
infection is an independent risk factor not only for the devel-
opment of CKD, but also for the rapid progression of CKD 
(ERCHIVES study) (18). Another study (19) confirmed that 
HCV-positive patients have a 40% higher chance of develop-
ing renal failure compared to HCV-negative patients. These 
findings were further confirmed by a systematic review and 
meta-analysis (20). In addition to being a risk factor for renal 
failure, HCV infection is also a risk factor for mortality in pa-
tients with end-stage renal disease (ESRD). A meta-analysis 
of 14 observational studies confirmed that HCV-Ab-positive 
serological status is an independent and significant risk factor 
for death in patients on dialysis (21). Similarly, a prospective 
observational study of 16,720 hemodialysis patients found 
that HCV positivity is associated with an increased risk of 
mortality (RR 1.17) (22). The Risk Evaluation of Viral Load 
Elevation and Associated Liver Disease/Cancer (REVEAL) 
HCV study is a large prospective community-based cohort 
study in Taiwan that provides an excellent opportunity to 
investigate the natural history of HCV infection and as-
sociated diseases (23). Recently, a study by Lai et al. (24) 
demonstrated that chronic HCV infection is an independent 
risk factor for the development of ESRD in patients with ge-
notype 1. Patients with low and high HCV-RNA levels had, 
respectively, 2.6- and 4.3-fold increased risk of developing 
ESRD compared with patients who were not infected with 
HCV (Figure 1). In a further study, Lai et al. demonstrated 
that, in addition to viral load, genotype 2 is a strong predic-
tor of CKD (25). The mechanism by which HCV infection 
increases the risk of morbidity and mortality in patients with 
CKD is not clear. About 50% of the deaths are related to 
cardiovascular diseases, and an association between malnu-
trition-inflammation syndrome (MIA syndrome) and poor 
Table 1. The major extrahepatic manifestations in patients 
with hepatitis C virus infection
Immune-related extrahepatic manifestations
- Mixed cryoglobulinemia
- Cryoglobulinemic vasculitis
- B-cell NHL
- Sicca syndrome
- Arthralgia/myalgia
-  Autoantibody production (cryoglobulins, rheumatoid 
factor, anticardiolipin, etc.)
- Polyarteritis nodosa
- Monoclonal gammopathies
- Immune thrombocytopenia
Inflammatory-related extrahepatic manifestations
- Type 2 diabetes mellitus
- Insulin resistance
- Glomerulonephritis
- Renal insufficiency
- Fatigue
- Cognitive impairment
- Depression
- Impaired quality of life
- Polyarthritis/fibromyalgia
-  Cardiovascular disorders (i.e. stroke and ischemic heart 
disease)
NHL, Non Hodgkin Lymphoma. 
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outcomes has been suggested (26). Other studies have high-
lighted that HCV has an atherogenic role, which could aggra-
vate metabolic syndrome (27).
HCV-associated renal diseases
HCV-related renal damage comprises several clinicopatho-
logical aspects that include glomerular and/or interstitial le-
sions (28–30) as summarized in Table 2. MPGN is the typical 
and most frequent pathologic entity. Kidney involvement may 
be the result of two different processes: the immune-mediated 
tissue damage or HCV-mediated direct injury. In addition, en-
vironmental or host factors, genetic background, decompen-
sated cirrhosis, and diabetes may contribute to renal damage 
in the setting of HCV infection. The HCV lymphotropism 
represents the main pathogenetic mechanism of HCV-related 
clinical manifestations. The HCV antigen is responsible for 
both T-lymphocyte and B-lymphocyte activation, leading to 
the production of autoantibodies and immune complexes in-
volved in the pathogenesis of HCV-related nephropathy (31). 
In addition, the virus per se may directly induce tissue dam-
age by infecting the endothelial, tubular, and epithelial cells, 
and infiltrating leukocytes. A high prevalence of occult HCV 
infection in patients with primary and secondary glomerular 
nephropathies (32, 33) and the presence of HCV antigen in 
kidney tissue of patients with various glomerulopathies (34) 
support the hypothesis of direct injury mediated by HCV.
Mixed cryoglobulins and MPGN
Among the HCV-related extrahepatic manifestations, cryo-
globulinemic vasculitis represents a severe condition often 
complicated by renal involvement (30). According to the 
type of immunoglobulins (Igs) involved, cryoglobulins (CGs) 
have been classified into type I, type II, and type III (35). 
Type I CG is frequently seen in monoclonal gammopathies 
like  multiple  myeloma or Waldenstrom’s macroglobuline-
mia. Types II and III CGs are a mix of both polyclonal IgG 
and monoclonal IgM with RF activity. Type II CG is mainly 
found secondary to infections such as HCV, hepatitis B virus 
(HBV), and human immunodeficiency virus. Type III CG 
is frequently associated with connective tissue diseases and 
rarely found in HCV-related MPGN. Mixed cryoglobulins 
(MCs) are the typical consequence of HCV infection and 
are often associated with MPGN. Types II and III MCs are 
generally present. A polyclonal IgG binds to another immu-
noglobulin, which acts as an antiglobulin and as an anti-IgG 
RF. HCV is known to be the cause of 80% of MCs. The pa-
thophysiological mechanism of HCV-related GN probably 
involves E2-CD81 interaction. The E2 protein of HCV in-
teracts with the CD81 that is the cellular receptor for HCV 
and is required for the infection of hepatocytes  (36). Type 
I MPGN is the most frequent GN associated with chronic 
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Figure 1. Cumulative risk of end-stage renal disease in 
patients affected by genotype 1 (24).
Table 2. Histopathological features of hepatitis C virus-related renal involvement
Renal disease pattern Histologic features Frequency
Diffuse or focal MPGN Mesangial cells proliferation plus deposits of immune 
complexes
Typically found
Mesangial proliferative GN Diffuse mild mesangial matrix expansion and mesangial 
cells proliferation
Occasionally found
Tubulointerstitial nephritis Interstitial fibrosis with negative immunofluorescence Rare
Membranous GN Subepithelial deposits of immune complexes Occasionally found
IgA nephropathy Mesangial IgA deposits Rare
Focal segmental glomerulosclerosis Sclerosed glomeruli and tubular atrophy, negative 
immunofluorescence
Rare
Immunotactoid glomerulopathy and 
fibrillary GN
Extracellular deposits of microfibrils; IgG and C3 
immunofluorescence
Rare
MPGN, membranoproliferative GN; GN, glomerulonephritis.
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HCV infection. The pathogenesis of MPGN is due to glo-
merular deposition of immune complexes often containing 
MCs; however, glomerular deposition of immune complexes 
in HCV-MPGN may be observed even in the absence of MCs 
(37). The immune complex deposits in the mesangium and 
subendothelium activate the complement system and mono-
nuclear cells, which alter glomerular permeability and cause 
subsequent cell damage through the release of proteases and 
oxidants (38). Overall, the prevalence of MPGN is higher in 
HCV patients with MCs. HCV-RNA has been observed in 
80% of patients with cryoglobulinemia-associated MPGN, 
but only in 25% of MPGN patients without cryoglobulinemia 
(38). MPGN may be associated with HCV infection indepen-
dently of circulating MCs. In such cases, the immunecom-
plexes  containing HCV are responsible for the GN. Viral 
nonstructural protein 3 (NS3) may be present in the deposits 
with a linear or granular pattern along the capillary walls and 
the mesangium (33).
Membranous Nephropathy
Several cases of membranous nephropathy (MN) have been 
described in HCV-infected patients (39, 40). The findings are 
similar to those observed in the classic idiopathic MN due 
to phospholipase A2 receptor (PLA2R). Complement level 
in the serum is normal and both CGs and RF are absent. 
Yamabe et al. (40) found that 8% of MN patients were HCV-
positive compared to less than 1% of patients with different 
forms of GN with the exclusion of MPGN.
Other glomerulonephritis
Diffuse proliferative GN with paramesangial dense IgM and 
C3 deposits may be occasionally observed in HCV-positive 
patients (41). The association of IgA nephropathy with HCV 
infection has been reported (42–44). Some of these reports 
describe a successful treatment with interferon alpha (IFNα). 
Several studies have highlighted the association between HCV 
and focal segmental glomerulosclerosis (FSGS) (45, 46). Shah 
et al. (46) reported that treatment with pegylated IFNα re-
sulted in a sustained virologic response (SVR), with a clinical 
remission lasting more than 5 years. Six cases of fibrillary im-
munotactoid glomerulopathies associated with HCV infection 
have been described (47–49). The best described are six cases 
by Markowitz et al. (47). They describe four cases of fibrillary 
GN and two cases of immunotactoid glomerulopathy asso-
ciated with HCV infection. The renal biopsy showed a mem-
branoproliferative pattern, but electron microscopy revealed 
fibrils of 16–28 nm diameter in fibrillary GN and 35–45 nm in 
immunotactoid glomerulopathy. Both fibrillary GN and im-
munotactoid glomerulopathy are similar to cryoglobulinemic 
GN, suggesting a common pathogenetic mechanism of orga-
nized glomerular deposits. In a review article, Johnson et al. 
(50) observed that patients affected by MPGN in association 
with HCV infection often have tubulointerstitial inflammation 
and scarring. More recently, in another study (51), tubuloin-
terstitial changes were frequently observed in HCV-infected 
patients, and the viral antigens and HCV-RNA were detected 
in the tubulointerstitium of these patients.
Kidney transplantation and HCV infection
The pre-transplant prevalence of  HCV infection has been re-
ported to be as high as 40% (52). In recent reports, the prev-
alence is lower due to the prophylactic measures adopted 
in CKD patients but still ranges from 3% to 80% (53). The 
survival of  HCV-positive RNA-positive kidney transplant 
recipients is poor, but higher with respect to HCV-positive 
RNA-positive patients who remain on dialysis (54–56); 
however, the survival rates in CKD and renal transplant pa-
tients have markedly improved after the introduction of  the 
DAA therapies. The most frequently reported HCV-related 
adverse events after kidney transplantation are acute and 
chronic graft dysfunction, infections, posttransplant diabe-
tes mellitus (PTDM), posttransplant lymphoproliferative 
disease, and GN (57). Cosio et al. (58) documented a high 
risk of  acute transplant glomerulopathy and acute vascu-
lar rejection in HCV-positive recipients. An increased risk 
of  chronic transplant glomerulopathy was documented in 
a meta-analysis of  eight clinical trials (59) and in another 
large single-center study (60). A higher incidence of  infec-
tions in HCV transplanted patients is debated, but a Spanish 
study with 1302 kidney transplant patients documented a 
higher incidence of  bacteremia and upper urinary infec-
tions (61). HCV infection is an independent risk factor for 
PTDM (62, 63). Virus-induced pancreatic β-cell dysfunc-
tion has been proposed as the pathogenetic mechanism (64). 
An increase in posttransplant lymphoproliferative disorders 
has been described in HCV patients transplanted with kid-
ney or other organs (65). Both recurrent and de novo GN 
have been observed in HCV renal transplant patients. HCV-
associated MPGN and MN recur after transplantation (66). 
The recurrence is more frequent after the second year and 
the incidence rate ranges from 20% to 30% for MPGN and 
from 3% to 7% for MN (67), similar to native kidney dis-
ease. HCV is also a risk factor for development of  de novo 
GN. One study reported an incidence rate as high as 63% for 
de novo GN (68). Similar findings were reported by others 
(69). De novo FSGS has also been reported in HCV renal 
transplant patients and a direct pathogenesis by HCV on 
podocyte has been suggested in such patients (11).
Treatment
The introduction of DAA drugs has remarkably ameliorated 
virus-mediated pathological changes in renal transplant pa-
tients. Relevant effects of these drugs are discussed in this 
section.
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History of HCV therapy
HCV is an enveloped virus with single stranded RNA and a 
genome composed of structural and nonstructural proteins 
(Figure 2) (6). Seven genotypes have been identified and di-
vided into subtypes and strains (70). The genotypes are dif-
ferentially distributed worldwide and the efficacy of DAA 
drugs may vary according to the HCV genotype. In the past, 
interferon-based regimen constituted the standard of care 
treatment. The first drug used was the recombinant alpha in-
terferon (IFNα) in combination with ribavirin. Initially, IFNα 
was used as monotherapy, but the efficacy in terms of SVR 
was poor, the treatment was expensive, and several side effects 
were reported. In addition, when used in transplant patients, it 
could generate severe acute rejection (71). On the other hand, 
when used in combination with ribavirin, the treatment leads 
to dose-dependent hemolytic anemia (72). Fabrizi et al. (73) 
performed a meta-analysis and concluded that the efficacy and 
safety of IFN-based therapies are unsatisfactory with low ef-
ficacy and high rate of side effects, particularly when used in 
transplant patients. This treatment was the standard of care 
until 1998. Later, the introduction of pegylated-IFNα in-
creased the SVR and it became the standard of care until 2011.
The knowledge of the mechanism of action of HCV and the 
viral proteins involved in its replication allowed for the devel-
opment of specific drugs for direct antiviral (DAA) treatment. 
The first generation of DAA was represented by boceprevir and 
telaprevir, which inhibit the NS3/4A protease activity. However, 
these drugs frequently induced viral resistance and therefore are 
combined with pegIFN and ribavirin. There are four classes of 
DAA agents based on their mechanisms of action (Table 3).
C E1 E2 P7 NS2 NS3 NS4A NS4B NS5A NS5B
5’NTR 3’NTR
Direct acng anvirals
NS3/4A inhibitors
Protease inhibitors
Simeprevir
Paritaprevir
Grazoprevir
NS5A
inhibitors
Daclatasvir
Ledipasvir
Ombitasvir
Elbasvir
Velpatasvir
NS5B 
inhibitors
Sofosbuvir
Dasabuvir
Structural proteins Nonstructural proteins
Figure 2. The hepatitis C virus genome and target sites of action of the direct-acting antiviral agents (6).
Table 3. The four classes of direct-acting antiviral agents
The four classes of DAAs Mechanism of action Drugs (targeted genotypes in brackets)
NS3/4A PIs Block a viral enzyme (protease) that enables the 
HCV to survive and replicates in the host cells
Simeprevir (1, 4)
Paritaprevir (1, 4)
Grazoprevir (1, 3, 4)
Nucleoside and nucleotide 
NS5B polymerase inhibitors
Target the HCV to stop replicating itself  in 
the liver
Sofosbuvir (1-4)
NS5A inhibitors Block a virus protein, NS5A, that HCV needs to 
replicate
Ombitasvirb (1, 4)
Pibrentasvir (1-6)
Daclatasvir (3)
Elbasvir (1, 4)
Ledipasvir (1)
Ombitasvir (1)
Velpatasvir (1-6)
Non-nucleoside NS5B 
polymerase inhibitors
Stop HCV from reproducing by inserting 
themselves into the virus so that other pieces of 
HCV cannot attach to it
Dasabuvir (1)
DAAs, direct-acting antivirals; HCV, hepatitis C virus.
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The first class includes the protease inhibitors (PIs) acting 
on NS3/4A. These drugs block a viral enzyme (protease) that 
enables the HCV to survive and replicate in host cells. The 
best-known drugs of this class are simeprevir and paritap-
revir acting on genotypes 1 and 4, and grazoprevir acting 
on genotypes 1, 3, and 4. These drugs are usually used in 
combination to achieve a stable SVR (74). The second class 
comprises nucleoside and nucleotide NS5B polymerase in-
hibitors that inhibit intrahepatic replication. The main drug 
belonging to this class is sofosbuvir. Sofosbuvir acts against 
genotypes 1–4 and was recently approved for use in combi-
nation with other DAAs. In particular, sofosbuvir has been 
studied in the HCV-TARGET study (75). As an increased 
rate of adverse events was observed in patients with renal 
failure, the current guidelines of the American Association 
for the Study of Liver Disease (AASLD) recommend that 
sofosbuvir should be used only in patients with an estimated 
glomerular filtration rate (eGFR) higher than 30 mL/min 
(74). The third class includes the NS5A inhibitors that block 
the virus protein NS5A, which is required for replication and 
various stages of infection. Several drugs belong to this class, 
which include ombitasvir (acting against genotypes 1 and 4), 
pibrentasvir (a pangenotype drug), daclatasvir (acting on 
genotype 3), elbasvir (acting on genotypes 1 and 4), ledipas-
vir (acting on genotype 1), and velpatasvir (a pan-genotype 
drug). A combination of ombitasvir/paritaprevir-ritonavir 
and dasabuvir is often used and represents the 3D regimen, 
marketed as Viekira Pak. This combination has been stud-
ied in the RUBY-I trial in CKD patients (76) obtaining a 
SVR without side effects. The fourth class of drugs includes 
dasabuvir, a non-nucleoside NS5B polymerase inhibitor that 
stops HCV from reproducing by inserting itself  into the 
virus so that other pieces of the HCV cannot attach to it. 
All the currently recommended regimens include at least two 
agents of different classes. The most common combination is 
a NS5A inhibitor with a polymerase inhibitor or a protease 
inhibitor. For resistant populations, the addition of ribavirin 
is recommended (77).
Treatment of HCV-related cryoglobulinemic GN
In the days of interferon therapy, peg-IFN or ribavirin 
(RBV) in combination with rituximab (RTX) was found to be 
more effective than peg-IFN or RBV alone in the treatment 
of HCV-associated MC (78, 79). Although the discovery of 
new DAAs has revolutionized the therapeutic approach, data 
on their efficacy in patients with HCV-associated cryoglob-
ulinemic vasculitis and GN are disappointing, probably due 
to the inability of the drugs to suppress the immune-medi-
ated process (80). RTX, in combination with DAA drugs, 
seems to have some impact on HCV-related cryoglobuline-
mic vasculitis. However, with the new generation of DAAs, 
the percentage of patients needing to receive concomitant 
immunosuppression is decreasing. Forty-three percent of 
patients treated with first-generation protease inhibitors re-
quired RTX or steroids, compared to 17% of patients treated 
with sofosbuvir (79, 81). In more recent studies on sofosbu-
vir-based therapy, only 4.5% of patients required RTX (82, 
83). In severe forms of cryovasculitis, it is necessary to use im-
munosuppression as a rescue therapy during treatment with 
DAAs (84), and complete remission of MC in response to 
combination therapy with DAA and RTX has been reported 
(85). All these findings have been incorporated in the recently 
published KDIGO guidelines (86). Accordingly, the recom-
mendation is that patients with HCV-related glomerular dis-
ease should be initially treated with DAA. For those patients 
who have flares or rapidly progressive kidney failure, in ad-
dition to DAA, immunosuppression should be used with or 
without plasma exchange. In the case of lack of response to 
DAA therapy, RTX treatment is recommended.
HCV treatment in patients with CKD
HCV infection is associated with a higher incidence of de-
creased eGFR, increased risk of CKD progression, and 
mortality. In a meta-analysis that included 890,560 patients, 
seropositive patients against HCV had a 70% increased risk 
of reduced eGFR (87) and in the REVEAL study, HCV-
positive patients had a lower eGFR and an increased risk of 
ESRD (47, 88). These data were confirmed by another study 
performed on US veterans (89). In this study, HCV positivity 
was associated with a deterioration of kidney function and 
the development of ESRD. Also, the NHANES III study 
confirmed a significantly higher microalbuminuria in HCV-
positive patients (90). In addition to specific renal diseases, 
cardiovascular disease and diabetes mellitus account for the 
rapid evolution of CKD in HCV patients (31). The discovery 
of DAA agents represented a relevant step in the evolution 
of HCV treatment by allowing to treat CKD patients inde-
pendently of the existence of an HCV-related specific neph-
ropathy. The aim of HCV treatment is to reach a stable SVR 
over time as documented by HCV serology and nucleic acid 
testing (NAT), 3 months after the end of treatment (91).
Most of the DAA studies in the general population in-
cluded patients with normal renal function and random-
ized controlled trials (RCTs) for CKD included patients 
with stages 4 and 5. As patients with CKD stages 1–3 are 
not considered a priority (87), data for these patients derive 
from post-marketing or real-world studies (92). In the TRIO 
Network, the combination of elbasvir and grazoprevir (EBR/
GZR) obtained a stable SVR, and about 50% were CKD 
stages 1–3 patients (93). The same combination was equally 
effective in a different study (94). The HCV TARGET data-
base (73) did not find any difference in SVR rates compar-
ing different CKD stages. This study as well as a study by 
Sise et al. (95) analyzed a sofosbuvir-based regimen. In this 
study, a sofosbuvir-based regimen reached a stable SVR inde-
pendently of the CKD stage. To date, the use of sofosbuvir is 
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only recommended for patients with an eGFR >30/mL/min, 
and investigations on the use of sofosbuvir in patients with 
ESRD are underway. Based on pharmacokinetic studies, so-
fosbuvir may accumulate in ESRD patients reaching an area 
under the curve (AUC) increase of 171%. Reports on safety 
of sofosbuvir in patients with ESRD are still sparse, and the 
available data are based on few studies with limited number 
of patients (96–98).
The use of DAAs in patients with CKD stages 4 and 5 (< 
30/mL/min) is confirmed by several studies and RCTs. In the 
C-SURFER study (99), a combination of grazoprevir and 
elbasvir achieved a stable SVR in ESRD patients affected by 
HCV genotype 1. This combination therapy was approved 
by the FDA in 2016. A retrospective analysis of this combi-
nation therapy confirmed its safety and efficacy (100). This 
is currently the recommended treatment for ESRD patients 
affected by genotype 1 or 4 (Table 4) (6). In August 2017, 
the FDA approved the pan-genotypic combination of gle-
caprevir (NS3/4 protease inhibitor) and pibrentasvir (NS5A 
inhibitor). The EXPEDITION-4 RCT investigated this com-
bination (101). The combination therapy administered to 
ESRD patients affected by genotypes 1–6 resulted in a stable 
SVR in 98% of patients, with few adverse events. The results 
of EXPEDITION-4 are encouraging but need confirmatory 
studies because of the small numbers of patients affected 
by genotypes 5 and 6. Even though DAA therapy is expen-
sive, recent studies documented that grazoprevir/elbasvir is 
cost-effective in the United States (102) and France (103).
The recently published KDIGO guidelines (104) are in line 
with these studies and recommend a combination of grazo-
previr/elbasvir for HCV patients with CKD stages 4 and 5 
(Table 5) (104). A relevant question is: “how and when a di-
alysis patient should be treated?” This is discussed by Davis 
et al. (105). RNA-positive patients with an active infection 
should undergo a complete evaluation of liver disease. If  they 
are affected by a severe decompensate cirrhosis, they should 
be listed for a combined liver–kidney transplant; otherwise, 
they can remain on dialysis and get treated for HCV. If  the 
liver evaluation shows only a mild activity with mild fibrosis, 
then the patients are transplant candidates, and there are two 
options. First, patients who are transplant candidates and 
have living donors should be treated immediately for HCV 
infection and transplanted if  found negative. Second,  pa-
tients who do not have living donors could be listed for HCV-
positive cadaver donor if  the transplant center accepts this 
activity or should wait for a cadaver donor and treat HCV 
while on dialysis and waiting (Figure 3). However, dialy-
sis patients who are not transplant candidates should also 
Table 4. Recommended direct-acting therapies by eGFR and viral genotype (AASLD/IDSA) (6)
Kidney function Viral genotype Recommended DAAs Rating of recommendation
eGFR >30 mL/min 
per 1.73 m2
1, 3 Daclatasvir (60 mg) 1, A
1, 4 Daily fixed-dose combination of elbasvir (50 mg)/
grazoprevir (100 mg)
1–6 Daily fixed-dose combination of glecaprevir (300 mg)/
pibrentasvir (120 mg)
1, 4, 5, 6 Daily fixed-dose combination of ledipasvir (90 mg)/
sofosbuvir (400 mg)
1–6 Daily fixed-dose combination of sofosbuvir (400 mg)/
velpatasvir (100 mg)
1 Simeprevir (150 mg)
1–6 Daily fixed-dose combination of sofosbuvir (400 mg)/
velpatasvir (100 mg)/voxilaprevir (100 mg)
1–4 Sofosbuvir (400 mg)
eGFR< 30 mL/min 
per 1.73 m2
1, 4 Daily fixed-dose combination of elbasvir (50 mg)/
grazoprevir (100 mg)
1, B
1–6 Daily fixed-dose combination of glecaprevir (300 mg)/
pibrentasvir (120 mg)
1, B
AASLD/IDSA, American Association for the Study of Liver Disease/ Infectious Diseases Society of America; DAA, direct-acting antiviral;  
eGFR, estimated glomerular filtration rate.
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receive treatment for HCV infection. We have already high-
lighted that HCV dialysis patients are affected by multiple 
hepatic and extrahepatic adverse events. Early data suggest 
a benefit with the new DAAs. The treatment cost does not 
justify withdrawing treatment for these patients, even if  they 
are not transplant candidates (106).
HCV treatment in transplant candidates before or 
after transplantation
The optimal timing to treat kidney transplant candidates is a 
matter of debate. On one hand, treatment before transplan-
tation decreases early posttransplant complications related 
to HCV infection. On the other hand, postponing treatment 
opens the possibility of transplanting a kidney from an 
HCV-positive donor, which means there is a shorter waiting 
time. Whether or not to treat HCV dialysis patients before 
transplantation is a concern that should be based on several 
considerations, such as the extent of liver damage, availabil-
ity of living donors, and extrahepatic manifestations of HCV. 
Patients with early cirrhosis without portal hypertension are 
considered for kidney-alone transplantation and the decision 
to treat with DAAs prior to transplantation also relies on 
other factors such as the availability of a living donor (107). In 
this scenario, it is better to treat before transplant if  the trans-
plant itself  is not imminent. Based on several studies, it could 
be said that the delay of transplantation should be individual-
ized according to specific conditions (108, 109). Extrahepatic 
manifestations of HCV include mixed cryoglobulinemic syn-
drome (MCS) and lymphoproliferative disorders. Patients 
Table 5. Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease G4-G5 and 
kidney transplant recipients by hepatitis C virus genotype (104)
Kidney function
HCV 
genotype
Recommended regimen
Strength of 
evidence
Alternate regimen
Strength of 
evidence
CKD G4–G5 (GFR 
<30 mL/min per  
1.73 m2 ) including 
kidney transplant
1a Grazoprevir/elbasvir 1B Ritonavir boosted 
paritaprevir, ombitasvir 
and dasabuvir
2D
Glecaprevir/pibrentasvir 1B Daclatasvir/asunaprevir 2C
1b Grazoprevir/elbasvir 1B Ritonavir boosted 
paritaprevir, ombitasvir 
and dasabuvir
2D
Glecaprevir/pibrentasvir 1B Daclatasvir/asunaprevir 2C
2, 3 Glecaprevir/pibrentasvir 1B
4 Grazoprevir/elbasvir 2D
Glecaprevir/pibrentasvir 1B
5, 6 Glecaprevir/pibrentasvir 2D
KTR (GFR> 30 mL/
min per 1.73 m2
1a Sofosbuvir with ledipasvir, 
daclatasvir, or simeprevir
1B Sofosbuvir/ribavirin 2D
Glecaprevir/pibrentasvir 1C
1b Sofosbuvir with ledipasvir, 
daclatasvir, or simeprevir
1B
Glecaprevir/pibrentasvir 1C
2, 3, 5, 6 Glecaprevir/pibrentasvir 1D Sofosbuvir/daclatasvir/
ribavirin
2D
4 Sofosbuvir with ledipasvir, 
daclatasvir, or simeprevir
1D
Glecaprevir/pibrentasvir 1D
KTR, Kiney transplant; CKD, chronic kidney disease; HCV, hepatitis C virus.
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with active HCV-associated MCS should undergo treatment 
before transplantation in order to avoid further complications 
(107). A regression of lymphoproliferative disorders related 
to HCV has been documented in 75% of patients (110). These 
patients too should be treated before transplantation.
The advent of DAAs made it possible to transplant HCV-
positive kidneys into HCV-positive recipients. Before the 
advent of DAAs, a large study documented the long-term sur-
vival of patients transplanted with HCV-positive kidney (111). 
In the era of DAA therapy, several studies have documented 
that transplantation of an HCV-positive kidney into an HCV-
positive recipient, and treatment with DAA post-transplant, 
had excellent outcomes, with stable SVR rates (112, 113). In 
addition, DAAs have allowed the transplantation of HCV-
infected kidneys into HCV-uninfected recipients. In addition 
to individual reports, two main studies examined this strategy. 
In the THINKER trial, patients were enrolled and treated a 
few days after transplantation with elbasvir and grazopre-
vir. Recipients became positive after transplantation, but an 
SVR was obtained in all the patients at 3 months (114). In the 
EXPANDER-1 trial, eight patients were transplanted in the 
same way. DAA therapy obtained an SVR in 3 months (115).
Colombo et al. (116) performed a phase 2 RCT to evalu-
ate the safety and efficacy of  the combination of  ledipasvir 
and sofosbuvir in 114 renal transplant patients with HCV 
genotype 1 or 4. SVR was obtained in all the patients with 
an excellent renal outcome. Saxena et al. (117) reported the 
efficacy of  DAA therapy in 443 patients who received either 
kidney transplant or liver transplant, or combined liver–
kidney transplant. The majority of  patients were treated 
with sofosbuvir/ledipasvir with or without RBV. DAA ther-
apy was effective and safe in both kidney and liver trans-
plantation. Reau et al. (118) in the MAGELLAN 2 study 
investigated the safety and efficacy of  glecaprevir and pi-
brentasvir in liver or kidney transplant patients. SVR was 
achieved in 99% of  patients, with a 100% kidney and graft 
survival. The 2017 AASLD (119) published the guidelines 
for kidney transplant patients, and the KDIGO guidelines 
recall what has been described above on the management 
of  HCV-infected patients before and after kidney trans-
plantation (Table 5) (120). One important concern with the 
new DAAs in kidney transplant patients is the drug inter-
actions with the immunosuppressive agents. Cyclosporine, 
tacrolimus, and sirolimus are metabolized in the liver by the 
cytochrome 450. As a result, for most DAAs, a substrate 
competition may occur, influencing their elimination. A 
careful dosage of  DAAs and immunosuppressive agents is 
therefore recommended (120).
HCV RNA TEST
No active infection: screen
Every 6 months
Active
infection
Mild activity/
Mild fibrosis
Stage liver disease
with fibroscan
Severe fibrosis/
Cirrhosis
Decompensated
Cirrhosis?
High Risk of Progressive Liver
Disease ?
Transplant
candidate?
Living Donor
Option?
RNA negative
Yes
List for combined
liver–kidney transplant
No
Yes
Treat HCV on dialysis
No No Treat HCV on
dialysis
Yes
Yes
Treat HCV on dialysis
or after transplant
No
List for HCV+
kidney
and treat HCV
after
transplant
Figure 3. Algorithm for hepatitis C virus antibody positive dialysis patients to determine timing of treatment (105).
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Conclusion
HCV infection is characterized by several extrahepatic dis-
orders, among which renal disorders are frequent and rel-
evant. Some of the HCV-related renal disorders include 
cryoglobulinemic GN, especially MPGN, higher incidence of 
progression to ESRD, and CKD-related mortality rate. The 
introduction of DAAs has revolutionized the management 
of HCV-mediated renal disorders. Cryoglobulinemic GN 
may be controlled using immunosuppressants in addition to 
DAAs. Patients at various stages of CKD may be treated for 
HCV to slow down the progression towards ESRD. Renal 
transplantation may be performed in HCV patients by treat-
ing them with DAAs before or soon after transplantation. 
Finally, HCV-positive kidneys may be given to HCV-positive 
or HCV-negative recipients by following specific guidelines.
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